Fate Therapeutics, Inc. (NASDAQ: FATE) Starts Presentation at 29th Annual ROTH Conference
Fate Therapeutics (NASDAQ: FATE) is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. The company's hematopoietic cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf product candidates derived from engineered induced pluripotent cell lines, and immuno-regulatory programs. Its adoptive cell therapy programs are based on the company's novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells. Fate Therapeutics is headquartered in San Diego, California. For more information, visit the company’s website at www.fatetherapeutics.com. About NetworkNewsWire NetworkNewsWire (NNW) provides…







